Treatment with our most effective ASO partially suppresses systemic inflammation in a mouse model of acute inflammation and prolongs survival in a murine model of CAPS, demonstrating that modulation of NLRP3 with splice-switching ASOs may have therapeutic value in treating NLRP3-driven inflammatory disease. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.